Compare BONESUPPORT HOLDING AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 13,165 Million (Small Cap)
84.00
NA
0.00%
-0.45
22.05%
13.86
Revenue and Profits:
Net Sales:
356 Million
(Quarterly Results - Jun 2026)
Net Profit:
82 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.7%
0%
-2.7%
6 Months
30.38%
0%
30.38%
1 Year
-29.2%
0%
-29.2%
2 Years
-18.81%
0%
-18.81%
3 Years
70.82%
0%
70.82%
4 Years
225.47%
0%
225.47%
5 Years
194.21%
0%
194.21%
BONESUPPORT HOLDING AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
45.38%
EBIT Growth (5y)
37.11%
EBIT to Interest (avg)
-9.08
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
1.27
Tax Ratio
28.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.47%
ROE (avg)
12.58%
Valuation key factors
Factor
Value
P/E Ratio
84
Industry P/E
Price to Book Value
16.98
EV to EBIT
53.46
EV to EBITDA
53.46
EV to Capital Employed
31.51
EV to Sales
12.75
PEG Ratio
1.54
Dividend Yield
NA
ROCE (Latest)
58.93%
ROE (Latest)
20.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
355.70
284.40
25.07%
Operating Profit (PBDIT) excl Other Income
85.10
66.30
28.36%
Interest
0.00
0.90
-100.00%
Exceptional Items
6.80
-2.80
342.86%
Consolidate Net Profit
81.90
53.10
54.24%
Operating Profit Margin (Excl OI)
239.20%
233.00%
0.62%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 25.07% vs 29.39% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 54.24% vs 93.80% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,174.70
898.70
30.71%
Operating Profit (PBDIT) excl Other Income
288.20
157.70
82.75%
Interest
3.30
2.30
43.48%
Exceptional Items
-31.20
0.00
Consolidate Net Profit
142.20
133.80
6.28%
Operating Profit Margin (Excl OI)
235.50%
163.50%
7.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 30.71% vs 52.04% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 6.28% vs -45.39% in Dec 2024
About BONESUPPORT HOLDING AB 
BONESUPPORT HOLDING AB
Pharmaceuticals & Biotechnology
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Company Coordinates 
Company Details
Scheelevagen 19 , LUND None : 223 70
Registrar Details






